Akero Therapeutics Inc

AKRO

NASDAQ. Currency in USD

38.77 -8.18 ( -17.41% )

Real time prices: December 19

Market Cap.
1.81B
Beta (5Y monthly)
-0.88
Price/Earnings
-
EPS (TTM)
-3.36
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
4.05M
1y Target Est.
50.33
Day's Range
35.80
-
41.23
52 Week's Range
7.52
-
48.38

Historical Summary

Performance
EPS growth
Share Buybacks

About Akero Therapeutics Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.akerotx.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
34.89M
Employees
34
Address
601 Gateway Boulevard, South San Francisco, CA, United States, 94080
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Latest news

Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session

Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced...
By Benzinga - 6 weeks ago

Deciphera's (DCPH) Q3 Loss Narrows, Qinlock Drives Revenues
Deciphera's (DCPH) Q3 Loss Narrows, Qinlock Drives Revenues

Deciphera (DCPH) reports a narrower-than-expected loss for the third quarter of 2022 while revenues beat...
By Zacks Investment Research - 13 weeks ago

Editas' (EDIT) Q3 Earnings Beat Estimates, Pipeline in Focus
Editas' (EDIT) Q3 Earnings Beat Estimates, Pipeline in Focus

Editas (EDIT) reports a narrower-than-expected loss for the third quarter of 2022. Focus remains on...
By Zacks Investment Research - 13 weeks ago

Acadia's (ACAD) Q3 Loss Narrower Than Expected, Revenues Miss
Acadia's (ACAD) Q3 Loss Narrower Than Expected, Revenues Miss

Acadia (ACAD) reports a narrower-than-expected loss in the third quarter of 2022 while revenues fall...
By Zacks Investment Research - 13 weeks ago

Alkermes (ALKS) Q3 Earnings Meet Estimates, Revenues Miss
Alkermes (ALKS) Q3 Earnings Meet Estimates, Revenues Miss

Alkermes' (ALKS) earnings meet estimates in the third quarter of 2022 while revenues miss the...
By Zacks Investment Research - 13 weeks ago

Novo Nordisk's (NVO) Q3 Earnings & Revenues Beat Estimates
Novo Nordisk's (NVO) Q3 Earnings & Revenues Beat Estimates

Novo Nordisk (NVO) reports better-than-expected Q3 results. Sales are aided by growth in Diabetes and...
By Zacks Investment Research - 13 weeks ago

Blueprint Medicines (BPMC) Q3 Earnings & Revenues Top Mark
Blueprint Medicines (BPMC) Q3 Earnings & Revenues Top Mark

Blueprint Medicines' (BPMC) earnings and revenues trump estimates for the third quarter of 2022. The...
By Zacks Investment Research - 13 weeks ago

Dr. Reddy's (RDY) Earnings & Revenues Trump Estimates in Q2
Dr. Reddy's (RDY) Earnings & Revenues Trump Estimates in Q2

Dr. Reddy's (RDY) earnings and sales beat estimates in second-quarter fiscal 2023.
By Zacks Investment Research - 13 weeks ago